PO.TB01.01 · 肿瘤生物学

Krüppel样因子8通过基质金属蛋白酶促进三阴性乳腺癌的血管生成和转移

Krüppel-like factor 8 promotes triple negative breast cancer angiogenesis and metastasis through matrix metalloproteinases

海报缩略图:Krüppel样因子8通过基质金属蛋白酶促进三阴性乳腺癌的血管生成和转移
编号 4792 展板 10 时间 4/21 09:00–12:00 区域 Section 25 主讲 Ebaa Ababneh, MD;MPH
分会场 Angiogenesis
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Ebaa Y. Ababneh, Heng Lu, Chunjiang He, Chao Shen, Lin Yu, Satadru K. Lahiri, Debarati Mukherjee, Xianhui Wang, Jihe Zhao

Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL

摘要 Abstract

中文摘要
Krüppel样因子8(KLF8)是一种已知可促进乳腺癌的转录因子。KLF8上调可降解细胞外基质(ECM)的基质金属蛋白酶(MMP),且与血管生成增强相关。然而,KLF8通过MMP在乳腺癌血管生成中的作用尚未阐明。我们假设,KLF8对MMP的上调通过降解ECM以创造物理空间并提高促血管生成因子的生物利用度,从而促进三阴性乳腺癌(TNBC,最具侵袭性的乳腺癌亚型)中的血管生成开关。我们采用可诱导的KLF8过表达(MCF10A-Ras)和敲低(MDA-MB-231)细胞模型在体外研究KLF8的功能。我们使用广谱基质金属蛋白酶(MMP)抑制剂GM6001以确认依赖性,采用内皮管腔形成和HUVEC募集实验评估血管生成潜能,采用定量实时PCR(qRT-PCR)和血管内皮生长因子(VEGF)-A ELISA测定生长因子表达和活性因子释放。随后使用体内异种移植肿瘤生长和尾静脉肺转移实验验证上述发现,通过微血管密度染色(分化簇31(CD31))对切除肿瘤中的血管生成进行定量评估,并采用MMP回复实验确立分子通路。我们的结果表明,KLF8过表达以MMP依赖的方式促进内皮细胞迁移和管腔形成。通过VEGFA ELISA确立了KLF8-MMP-VEGF轴,其显示条件培养基中活性VEGF以KLF8依赖的方式积累。该效应被MMP抑制所消除。值得注意的是,KLF8确实影响VEGF mRNA的表达。体内实验验证了这些结果,显示KLF8过表达显著增加血管生成、异种移植肿瘤生长和肺转移。另一方面,在敲低细胞中回复MMP-9或MMP-14可恢复KLF8敲低所产生的效应。在人乳腺癌队列中,高KLF8表达与较差的无远处转移生存期及血管生成标志物升高相关。总之,我们的工作证明了KLF8通过激活MMP9和MMP14促进TNBC转移的作用,后者进而通过释放可溶性VEGF增强血管生成微环境。本工作深化了我们对KLF8致癌功能的理解,并提示KLF8-MMP信号可能是TNBC一个有前景的抗血管生成治疗靶点。
查看英文原文 English abstract
Krüppel-like factor 8 (KLF8) is a transcription factor known to promote breast cancer. KLF8 upregulates matrix metalloproteinases (MMPs) that degrade the extracellular matrix (ECM) and are associated with enhanced angiogenesis. However, KLF8's role in BC angiogenesis through MMPs has not been elucidated. We hypothesize that KLF8's upregulation of MMPs promotes an angiogenic switch in triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, by degrading the ECM to create physical space and increase the bioavailability of pro-angiogenic factors. Inducible KLF8 overexpression (MCF10A-Ras) and knockdown (MDA-MB-231) cell models were used to study the function of KLF8 in vitro . We employed the broad-spectrum matrix metalloproteinase (MMP) inhibitor GM6001 to confirm dependency, endothelial tube formation and HUVEC recruitment assays to evaluate angiogenesis potential, Quantitative real-time PCR (qRT-PCR) and Vascular Endothelial Growth Factor (VEGF)-A ELISA to measure growth factor expression and active factor release. Findings were then validated using the in vivo xenograft tumor growth and tail vein lung metastasis assays, angiogenesis in excised tumors was quantitatively evaluated using microvessel density staining (cluster of differentiation 31 (CD31)), with MMP rescue experiments used to establish molecular pathway. Our results show that KLF8 overexpression promotes endothelial cell migration and tube formation in an MMP-dependent manner. The KLF8-MMP-VEGF axis is established using VEGFA ELISA that shows KLF8-dependent accumulation of active VEGF in conditioned medium. This effect was eliminated by MMP inhibition, Notably, KLF8 does affect VEGF mRNA expression. In vivo experiments validate these results showing that KLF8 overexpression markedly increases angiogenesis, xenograft tumor growth, and lung metastasis. On the other hand, MMP-9 or MMP-14 rescue in the knockdown cells restores the effects of KLF8 knockdown. Poor distant metastasis-free survival and elevated angiogenic markers are associated with high KLF8 expression in human breast cancer cohorts. In conclusion, our work demonstrates KLF8's role in promoting TNBC metastasis by activating MMP9 and MMP14, which in turn enhances the angiogenic microenvironment through the release of soluble VEGF. This work advances our understanding of KLF8's carcinogenic function and suggests that KLF8-MMP signaling could be a promising antiangiogenic therapeutic target for TNBC.
利益披露 Disclosure
E. Y. Ababneh, None.. H. Lu, None.. C. He, None.. C. Shen, None.. L. Yu, None.. S. K. Lahiri, None.. D. Mukherjee, None.. X. Wang, None.. J. Zhao, None.

← 返回 AACR 2026 检索